143536-99-6 Usage
Description
4-METHOXYPHENYL 2,3,4,6-TETRA-O-BENZYL-BETA-D-GALACTOPYRANOSIDE is a white fine crystalline powder with significant therapeutic potential. It is a complex organic compound derived from galactopyranosides, which are sugars commonly found in nature. 4-METHOXYPHENYL 2,3,4,6-TETRA-O-BENZYL-BETA-D-GALACTOPYRANOSIDE has been studied for its ability to inhibit the formation of abnormal prion proteins, which are associated with various neurodegenerative diseases.
Uses
Used in Pharmaceutical Industry:
4-METHOXYPHENYL 2,3,4,6-TETRA-O-BENZYL-BETA-D-GALACTOPYRANOSIDE is used as a therapeutic agent for its potential to inhibit the formation of abnormal prion proteins. This application is particularly relevant in the treatment and prevention of neurodegenerative diseases, such as Creutzfeldt-Jakob disease, Gerstmann-Str?ussler-Scheinker syndrome, and fatal familial insomnia, which are caused by the accumulation of these misfolded proteins in the brain.
Used in Research and Development:
In addition to its potential pharmaceutical applications, 4-METHOXYPHENYL 2,3,4,6-TETRA-O-BENZYL-BETA-D-GALACTOPYRANOSIDE is also used as a research tool in the study of prion protein biology and the development of novel therapeutic strategies for prion-related diseases. Its unique chemical properties make it a valuable compound for investigating the molecular mechanisms underlying prion protein misfolding and aggregation, as well as for screening and identifying potential drug candidates that can modulate these processes.
Used in Drug Delivery Systems:
Similar to gallotannin, 4-METHOXYPHENYL 2,3,4,6-TETRA-O-BENZYL-BETA-D-GALACTOPYRANOSIDE may also benefit from the development of novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. By employing various organic and metallic nanoparticles as carriers, researchers can improve the compound's ability to reach target cells and tissues, potentially leading to more effective treatments for prion-related diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 143536-99-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,3,5,3 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 143536-99:
(8*1)+(7*4)+(6*3)+(5*5)+(4*3)+(3*6)+(2*9)+(1*9)=136
136 % 10 = 6
So 143536-99-6 is a valid CAS Registry Number.
InChI:InChI=1/C41H42O7/c1-42-35-22-24-36(25-23-35)47-41-40(46-29-34-20-12-5-13-21-34)39(45-28-33-18-10-4-11-19-33)38(44-27-32-16-8-3-9-17-32)37(48-41)30-43-26-31-14-6-2-7-15-31/h2-25,37-41H,26-30H2,1H3/t37-,38+,39+,40-,41-/m1/s1
143536-99-6Relevant articles and documents
Synthesis and conformational analysis of vicinally branched trisaccharide β-d-Galf-(1 → 2)-[β-d-Galf-(1 → 3)-]-α-GalpfromCryptococcus neoformansgalactoxylomannan
Dorokhova, Vera S.,Gerbst, Alexey G.,Komarova, Bozhena S.,Previato, José O.,Previato, Lúcia Mendon?a,Dmitrenok, Andrey S.,Shashkov, Alexander S.,Krylov, Vadim B.,Nifantiev, Nikolay E.
, p. 2923 - 2931 (2021/04/14)
The synthesis of a vicinally branched trisaccharide composed of twod-galactofuranoside residues attachedviaβ-(1 → 2)- and β-(1 → 3)-linkages to the α-d-galactopyranoside unit has been performed for the first time. The reported trisaccharide represents the galactoxylomannan moiety first described in 2017, which is the capsular polysaccharide of the opportunistic fungal pathogenCryptococcus neoformansresponsible for life-threatening infections in immunocompromised patients. The NMR-data reported here for the synthetic model trisaccharide are in good agreement with the previously assessed structure of galactoxylomannan and are useful for structural analysis of related polysaccharides. The target trisaccharide as well as the constituent disaccharides were analyzed by a combination of computational and NMR methods to demonstrate good convergence of the theoretical and experimental results. The results suggest that the furanoside ring conformation may strongly depend on the aglycon structure. The reported conformational tendencies are important for further analysis of carbohydrate-protein interaction, which is critical for the host response towardC. neoformansinfection.
Catalytic glycosylation with rhodium(III)-triphos catalysts
Wagner, Beatrice,Heneghan, Michael,Schnabel, Gerhard,Ernst, Beat
, p. 1303 - 1306 (2007/10/03)
The formation of glycosides in high yield from 1-hydroxy sugars using catalytic amounts (0.5molpercent) of Rh(III)Cl3(triphos) (1a) or [Rh(III)(MeCN)3(triphos)](TfO)3 (1b) is described. High stereocontrol at the anomeric c
159. Glycosylidene Carbenes - Part 2 - Synthesis of O-Aryl Glycosides
Briner, Karin,Vasella, Andrea
, p. 1764 - 1779 (2007/10/02)
Phenol, 4-methoxyphenol, 4-nitrophenol, methyl orsellinate (1), and 2,6-di(tert-butyl)-4-methylphenol (BHT; 2) have been glycosylated by thermal reaction (20-60 deg C) with various glycosylidene-derived diazirines. 4-Methoxyphenol reacted with the D-gluco
